Parallel Advisors, LLC Biogen Inc. Transaction History

Parallel Advisors, LLC

$4.34 Billion
Q4 2024

A detailed history of Parallel Advisors, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 1,320 shares of BIIB stock, worth $186,687. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,320

Previous 1,545 14.56%

Holding current value

$186,687

Previous $299,000 32.78%

% of portfolio

0.0%

Previous 0.01%

35 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 10, 2025	SELL	$146.47 - $191.55 $32,955 - $43,098	-225 Reduced 14.56%	1,320 $201,000
Q3 2024 Nov 13, 2024	SELL	$189.07 - $236.8 $82,623 - $103,481	-437 Reduced 22.05%	1,545 $299,000
Q2 2024 Aug 08, 2024	BUY	$190.52 - $236.72 $29,721 - $36,928	156 Added 8.54%	1,982 $459,000
Q1 2024 May 06, 2024	SELL	$212.02 - $267.71 $15,901 - $20,078	-75 Reduced 3.95%	1,826 $393,000
Q4 2023 Feb 09, 2024	SELL	$222.59 - $267.94 $7,345 - $8,842	-33 Reduced 1.71%	1,901 $491,000
Q3 2023 May 20, 2024	SELL	$253.3 - $285.89 $25,076 - $28,303	-99 Reduced 4.87%	1,934 $497,000
Q3 2023 Nov 13, 2023	SELL	$253.3 - $285.89 $25,076 - $28,303	-99 Reduced 4.87%	1,934 $497,000
Q2 2023 May 20, 2024	BUY	$275.25 - $318.06 $11,560 - $13,358	42 Added 2.11%	2,033 $579,000
Q2 2023 Aug 04, 2023	BUY	$275.25 - $318.06 $11,560 - $13,358	42 Added 2.11%	2,033 $579,000
Q1 2023 May 20, 2024	BUY	$256.56 - $292.34 $42,332 - $48,236	165 Added 9.04%	1,991 $553,000
Q1 2023 Apr 25, 2023	SELL	$256.56 - $292.34 $14,623 - $16,663	-57 Reduced 2.78%	1,991 $553,000
Q4 2022 Feb 03, 2023	BUY	$252.44 - $306.72 $73,460 - $89,255	291 Added 16.56%	2,048 $567,000
Q3 2022 Nov 10, 2022	SELL	$194.69 - $268.46 $3,115 - $4,295	-16 Reduced 0.9%	1,757 $469,000
Q2 2022 Aug 01, 2022	SELL	$187.54 - $223.02 $14,815 - $17,618	-79 Reduced 4.27%	1,773 $362,000
Q1 2022 Apr 28, 2022	SELL	$193.77 - $244.14 $28,677 - $36,132	-148 Reduced 7.4%	1,852 $391,000
Q4 2021 Jan 20, 2022	SELL	$223.92 - $287.77 $42,992 - $55,251	-192 Reduced 8.76%	2,000 $480,000
Q3 2021 Nov 02, 2021	BUY	$282.99 - $369.05 $6,225 - $8,119	22 Added 1.01%	2,192 $620,000
Q2 2021 Aug 06, 2021	BUY	$259.0 - $414.71 $51,023 - $81,697	197 Added 9.98%	2,170 $751,000
Q1 2021 Apr 23, 2021	SELL	$242.95 - $284.63 $4,373 - $5,123	-18 Reduced 0.9%	1,973 $552,000
Q4 2020 Feb 02, 2021	BUY	$236.26 - $355.63 $34,966 - $52,633	148 Added 8.03%	1,991 $488,000
Q3 2020 Oct 27, 2020	BUY	$264.77 - $305.71 $15,091 - $17,425	57 Added 3.19%	1,843 $523,000
Q2 2020 Jul 16, 2020	SELL	$258.66 - $342.55 $187,528 - $248,348	-725 Reduced 28.87%	1,786 $477,000
Q1 2020 Apr 27, 2020	BUY	$268.85 - $341.04 $223,145 - $283,063	830 Added 49.38%	2,511 $794,000
Q4 2019 Jan 30, 2020	SELL	$220.06 - $304.07 $51,714 - $71,456	-235 Reduced 12.27%	1,681 $499,000
Q3 2019 Nov 01, 2019	BUY	$217.44 - $243.88 $163,080 - $182,910	750 Added 64.32%	1,916 $446,000
Q2 2019 Aug 05, 2019	SELL	$219.29 - $241.72 $45,831 - $50,519	-209 Reduced 15.2%	1,166 $273,000
Q1 2019 May 01, 2019	SELL	$216.71 - $338.96 $21,887 - $34,234	-101 Reduced 6.84%	1,375 $325,000
Q4 2018 Feb 05, 2019	BUY	$278.5 - $352.75 $22,280 - $28,220	80 Added 5.73%	1,476 $443,000
Q3 2018 Nov 01, 2018	BUY	$293.51 - $383.83 $13,794 - $18,040	47 Added 3.48%	1,396 $492,000
Q2 2018 Jul 30, 2018	BUY	$257.52 - $306.91 $56,654 - $67,520	220 Added 19.49%	1,349 $391,000
Q1 2018 May 08, 2018	BUY	$260.13 - $367.91 $19,769 - $27,961	76 Added 7.22%	1,129 $309,000
Q4 2017 Feb 13, 2018	BUY	$307.64 - $344.58 $13,536 - $15,161	44 Added 4.36%	1,053 $335,000
Q3 2017 Nov 15, 2017	BUY	$281.15 - $329.69 $283,680 - $332,657	1,009 New	1,009 $319,000
Q3 2017 Nov 14, 2017	SELL	$281.15 - $329.69 $283,399 - $332,327	-1,008 Closed	0 $0
Q2 2017 Aug 07, 2017	BUY	N/A	1,008	1,008 $292,000

Others Institutions Holding BIIB

# of Institutions

1,007

Shares Held

131M

Call Options Held

1.77M

Put Options Held

2.34M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $20.4B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.

Account

Parallel Advisors, LLC Biogen Inc. Transaction History